MedTrace Logo

Evaluation of the Efficacy and Tolerance of B-Back® on the Burnout Syndrome

NCT01599169 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2013-04-23

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and the tolerance of the food supplement B-Back®, containing α-casozepine, taurine, eleutherococcus senticosus and Extramel®, on the burnout syndrome.

Conditions

  • Efficacy and Tolerance of B-Back® on the Burnout Syndrome

Interventions

DIETARY_SUPPLEMENT

Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)

2 tablets/day after breakfast during 12 weeks

DIETARY_SUPPLEMENT

B-Back® placebo (without active compounds)

2 tablets/day after breakfast during 12 weeks

Sponsors & Collaborators

  • Nanox International Laboratory (Belgique)

    collaborator UNKNOWN

  • Université Victor Segalen Bordeaux 2

    lead OTHER

Principal Investigators

  • Nicholas Moore, MD, PhD · Université Victor Segalen Bordeaux 2

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01599169 on ClinicalTrials.gov